Navigation Links
Pier Paolo Pandolfi, M.D., Ph.D., to receive Pezcoller-AACR International Award for Cancer Research
Date:1/12/2011

BOSTON Beth Israel Deaconess Medical Center cancer geneticist Pier Paolo Pandolfi, MD, PhD, is the recipient of the 2011 Pezcoller Foundation-AACR (American Association of Cancer Research) International Award for Cancer Research. This is the second time in the award's 14-year history that a BIDMC investigator has received this prestigious honor, which was established in 1997 to recognize a scientist of international renown who has made a major scientific discovery in either basic or translational cancer research.

"The BIDMC research community is extraordinarily proud of Dr. Pandolfi and of this award," says Chief Academic Officer Vikas Sukhatme, MD, PhD. "Pier Paolo now joins Lew Cantley as the second BIDMC investigator to receive the Pezcoller, the only time in the award's history that two investigators from the same institution have been recognized. This speaks to BIDMC's position as a world-class leader in cancer research and to the outstanding contributions being made by the BIDMC Cancer Center in translating molecular discoveries into patient treatments."

Pandolfi joined the BIDMC faculty in 2007, where he serves as Chief of the Division of Genetics in the Department of Medicine, Director of Research in the BIDMC Cancer Center, and director of the cancer genetics program. The George C. Reisman Professor of Medicine at Harvard Medical School, Pandolfi was recognized by the Pezcoller Foundation and the AACR for both his outstanding work in the field of cancer genetics, and for his groundbreaking development of cancer mouse models.

"Dr. Pandolfi's research has led to major breakthroughs in our essential understanding of how mutations in oncogenes and tumor suppressor genes result in leukemias, lymphomas and solid tumors," adds BIDMC Cancer Center Director Lewis Cantley, PhD, who received the Pezcoller award in 2005. "His pioneering work in developing transgenic mouse models of cancer helped lead to novel therapeutic strategies for acute promyelocytic leukemia [APL], and, today, this unique expertise in mouse-model engineering is helping to speed the clinical testing of new personalized cancer therapies."

Among his many accomplishments, Pandolfi's prolific laboratory has characterized the function of oncoproteins and genes involved in the chromosomal translocations of APL, as well as of major tumor suppressors such as PTEN and p53, and novel proto-oncogenes, such as POKEMON. More recently, Pandolfi's laboratory challenged a central dogma of molecular biology with the discovery of a novel and critically important new role for messenger RNA that includes previously unrecognized biological functions for both coding and noncoding mRNA.

"I'm extremely honored to receive the Pezcoller award," says Pandolfi. "This is a tremendously exciting time I would even say revolutionary for cancer research and I'm thrilled to be a part of it. As we now clearly recognize, 'cancer' is not a single disease, but is made up of many, many different mutations. While this provides us with unprecedented opportunities for developing personalized treatments, our ultimate goal is to understand and cure cancer, and this award gives us further motivation to achieve this goal as we continue to fight relentlessly for the sake of our patients."

A native of Rome, Pandolfi received his MD in 1989 and PhD in 1995, both from the University of Perugia, Italy. He completed post-graduate work at the Royal Postgraduate Medical School, University of London, before joining the faculty of Memorial Sloan-Kettering Cancer Center and the Weill Graduate School of Medical Sciences at Cornell University in 1994.

Pandolfi is the recipient of numerous awards and honors, including a National Institutes of Health/National Cancer Institute MERIT Award; the Leukemia and Lymphoma Society of America Stohlman Scholar Award; the Weizmann Institute of Science: Sergio Lombroso Prize for Cancer Research; the William and Linda Steere Foundation Award; and the prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation. He has also been awarded the Fondazione Cortese International Award; the Prostate Cancer Foundation Creativity Award; and the Ischia International Award.

In 2006, Pandolfi was elected as a member of the American Society for Clinical Investigation and the American Association of Physicians, and in 2007 became a member of the European Molecular Biology Organization. He is the author of more than 300 papers.

Pandolfi will deliver an award lecture entitled "The Non-Coding Revolution: A Coding-Independent Function of Gene and Pseudogene mRNAs Regulates Tumour Biology" during the 102nd Annual Meeting 2011 of the American Association for Cancer Research in Orlando, Florida, this spring.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Donald M. Lloyd-Jones, M.D., recipient of the American Heart Associations 2010 Chairmans Award
2. Douglas A. Jabs, M.D., honored with Jackson Memorial Lecture by the American Academy of Ophthalmology
3. O. Marion Burton, M.D., F.A.A.P., addresses American Academy of Pediatrics in new term as president
4. Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study
5. Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World
6. Gino Tutera, M.D., F.A.C.O.G. Brings SottoPelle Therapy to Middle Tennessee, Opens Practice in Nashville Medical District
7. Joan Miller, M.D., receives 2010 Leadership Award for the Advancement of Women Faculty
8. University of Utah afib specialist, Marcos Daccarett, M.D., wins Young Investigator Award
9. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
10. AMA Honors Vice Admiral John Mateczun, M.D., With Top Government Service Award
11. AnaLisa DiFeo, Ph.D., recognized with the Liz Tilberis Scholarship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... BOSTON, MA (PRWEB) , ... June 27, 2017 , ... ... U.S. Senate bill to repeal and replace the 2010 Patient Protection and Affordable Care ... as compared with what would be expected under current law. , More than 20 ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... assistance and personal financial planning services to residents of southern New Hampshire, is ... event that promises to fight hunger and homelessness in the region. , New ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National Basketball ... NBSCA Strength & Conditioning Coach of the Year. , In its 11th year, ... the coach who embodies the highest level of excellence and outstanding service to their ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Torrance dentist, ... aesthetics can be one of the most noticeable aspects of a person’s appearance. A ... not everyone is born with beautiful, balanced teeth, everyone can have the smile of ...
(Date:6/26/2017)... ... June 26, 2017 , ... A new and improved Orgasm-Shot ... look and feel about themselves and their sexual encounters. A unique medical practice ... leakage head on with a ground breaking medical technique aimed to give women ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology: